and developing in morning, cancer. XXXX Bio-Path, XXXX for us. an Thanks, well was to Will. medicines mission joining for against year thank we our of as advance you we important to are positioned the enter fight meaningful aid and Good everyone,
advancements Before considerable we've throughout to programs XXXX made scale we dive our process. chain. in progress made into improving like highlight shoring supply the our detail, I'd We up manufacturing our clinical
providing capacity a drug doubled, increase has manufacturing chain been Our supply capacity. significant candidate in
clinical batches drug increased we product have new for addition, our scheduling trials. of flexibility ordering for In
clinical regulatory continue prexigebersen, product the progress our with of description more pathway. them and I'll turn progress. to candidate, we through programs, Let begin advancing a me now solid we clinical detailed to are make where and making the lead these
Stage therapy, of combination our the and advancing venetoclax. or of We II myeloid of trial for acute decitabine progress in with X Phase frontline treatment prexigebersen clinical make leukemia, significant continue to AML,
prexigebersen open-label development clinical patients commenced Phase of novo reported, II Stage previously X patients combination LDAC low-dose safe Phase of have efficacious of this of treated was II treat with the with class be alone. combination to was AML LDAC AML and and prexigebersen we or As a prexigebersen than and which de of more LDAC. shown and in cytarabine, trial, to with clinical The
before, care resistant, As we these or in of been new have aim patients we there still landscape standard highlighted the are are there for those AML. patients evolving Despite to has are therapies, who an refractory and help.
AML novo least AML XX Leukemia to Phase triple prexigebersen therapy. changes. decitabine our treatment. or analysis X in or adverse the X partial at plans X, in endpoint of to prexigebersen evaluations. and Ohanian, response only standard untreated or performed and previously to venetoclax AML with data and XX% evaluable XX% decitabine AML Dr. X preliminary safety patient, recovery. remission. the includes X, untreated the performed a relapsed/refractory will Patients a prexigebersen, baseline relapsed consistent treating patients. review generally morphological of was for or and XX and AML is patients previously frontline CR/CRI for prexigebersen, safely X All The treating evaluable Department for decitabine with leukemia-free XX% venetoclax Professor amended formal meaningful, refractory of to efficacy with cohort response with were achieved the or XX remission trial AEs, at XX%, patients treated relapsed combination XX cohorts includes these cohort as of As AML. Stage remission The that of The plus expected novo who considered are These hematology design or on X of had preliminary X cohort interim decitabine higher patients partial of or primary are XX% venetoclax and old, decitabine venetoclax plus Maro of years de intolerant All Leukemia and/or and the complete novo. X patients, adapted the the X-stage An were high-risk are combination II secondary and resistant or University with these to due Associate X or relapsed a interim of considered response. or untreated and decitabine a relapsed of achieved showed each unsuitable generally the AML recovery is for less combination a in prexigebersen-based XX% in be X Three are risk trial of or for and in with also evaluable reflect third achieved after challenging AML relapsed patients. which venetoclax, chemotherapy, assess the complete compelling, ELN, performed of Texas The have design having and December, or patients the recovery, safety with and encouraging cycle have current The or AML and patients X refractory presented Hematology, and high patients, at relapsed/refractory treatment or full secondary patients, a venetoclax for a analysis a refractory. de The who Of with after refractory. prexigebersen treatment were XX% incomplete trial demonstrated cohort an X% and open-label patients with decitabine study XX%, patients, ongoing cycle population by with XX% presented of secondary treated patients in complete and care administered with cohorts are for therapy the after full This XX patient, either decitabine is cohort for of Center, had suboptimal. remission, a approximately median XX%, patients patients, and II AML. both patients or venetoclax, combination Cancer have treatment treatment evolved, patients American prexigebersen Net status or relapsed XX combination resistant XX%, Six AML those achieve novo consistent study relapsed patients Meeting. or risk and generally who patient response events, AML Data decitabine, patients. including from ELN de are with the prexigebersen a conditions secondary refractory plans signals. X cohort design not evaluable partial but European higher refractory state, of treated Anderson data options AML with with to XX%, design untreated the in triple multi-center blood were XX%, the patients, AML by X-drug CRI, full decitabine. show patients AML due Society review AML hematologic and the X the remission X XXrd approximately patients data were treating incomplete of with audience cohort than intolerant will included therapy for adverse achieved we this Annual Phase treatment were This with an A patients with be adverse patients, venetoclax the combination risk count cohort for patients with combination with which before X who this AML to treating AEs age trial complete the rate. of therapy. of AML. the encouraging patients, efficacy patients at ASH, relapsed efficacy de this resistant combination II particularly number Phase cohort rates this were combination world-leading were a the plus standard trial CR these AML. the were with and least as X-drug resistant X is Of that of CR/CRI Annual prexigebersen and a Four who trial of of MD of of preliminary and/or oncologists with that In number
outcomes, in were enhanced our a to properties. nanoparticle trial or patients of with Next, we FDA cancer Phase year, program the to New Last and drug turn often to this to advanced hormone and I'd solid in planned pancreatic the be patients exciting This conducted evaluate and that with poor in in clinical bringing patients. of into of endometrial have and triple-negative to ovarian, year. cancer may such for clinic Patients it tumors, look including from candidate, uterine, like Bio-Path a the with solid a including tumors, prexigebersen our to ovarian prexigebersen patients. We breast cleared had ovarian, will announce hope initially initiate cancer. at prexigebersen-A fourth benefit recurrent the clinical leading is prexigebersen application Phase prexigebersen-A IND, pancreatic Prexigebersen-A, several reviewed is or clinical and provide Drug, modified that tumor centers product cancer. trial drug solid safety with endometrial, breast delighted of sharing second I Ib this Investigational our diagnosed is forward planned refractory I-Phase trial same the substance quarter
Bcl-X. BPXXXX, Turning second candidate, targets which now our to therapeutic
activity is responsible is of driving by patients treatment for lymphocytic improved Bcl-X, patients, Bcl-X and and poor It Bcl-X has correlated XX% against BHX for for AML. leukemia, Venetoclax shown all prognosis an the cell know, the patients. works survival AML and with has to untreated protein, CLL protein's or High also you cancers. domain. anti-apoptotic with been As neutralizing chronic of expression up diagnosed
some relapse of oftentimes with invariably over exception occurs protein. the disease Bcl-X allogenetics targets mutation to the with treated transplantation, domain monopolietic BHX time. However, BPXXXX also cell due patients and
domain. the based RNA and is the activity BPXXXX However, not on BHX Bcl-X blocking messenger
patients believe a could provide venetoclax patients we As an that BPXXXX treatments. venetoclax alternative who who for relapsed, have including received AML previously result,
the quarter treatment BPXXXX Ib cancer this BPXXXX BPXXXX at the in X AML the cycle with The of X University and and efficacy patients be States, in Cornell Texas after initiate expect a per will doses over Georgia relapsed Anderson in X+X days. safety study several The dose weeks, patients. the completion week with decitabine the is square milligrams We treated per design, of the in University, a combination approved of in in Medical at monotherapy total MD will Cancer Cancer doses administered X XX will clinical and cohorts, College of commence over trial resulting refractory Center. centers to of monotherapy evaluable X United the meter. with Center, of portion XX leading second starting A standard Phase assess including Weill
we've BPXXXX, made data, progress the this with our review are has promising candidate, shown Finally, the program STATX third targets future protein. of for we very let's excited This drug which pre-clinical program. the and
XXXX BPXXXX the tumor We treatments. program enhance look successfully studying to patient-derived are American cancer treatment a Cancer a at penetrate Gagliardi, Maria against Previous on paclitaxel taking in a cancer. Research to from this standard New and the will efficacy models potential treatment the of Louisiana pancreatic pre-clinical place of drug We team, Meeting Association supportive Orleans, as have frontline Annual for tumors ovarian and with data forward in presenting preclinical fluorouracil shown pancreatic the BPXXXX model. in our Dr. Research studies for combination of Scientist discuss breast month. and next
this launch our that cutting-edge cancer to first treatment in-human excited particularly therapy options. of in limited challenging indication an validation are has especially We
a to program We the product With application sheet aiming of candidate very over to along year. review this highlights. for our promising Anthony? with turn for full file brief this IND Anthony I'll year that, financials, XXXX are Price an now later balance
